TriangleDISEASE & TREATMENT SETTING
Carcinoma In Situ
Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.
Exact scope
Carcinoma In Situ
- Source population
- Not part of this definition
- Disease extent
- Not part of this definition
- Treatment line
- Not part of this definition
- Stage
- Not part of this definition
- Resectability
- Not part of this definition
Biomarkers, prior therapy and derivation
- molecular
- prior therapy
- derivation status
- source-attested
- derivation note
- Added because the terminology and the registry both attest it: an NCIt neoplasm concept named by 1 acquired study condition(s). It is absent from the NCI treatment-topic directory, which is not an exhaustive cancer inventory.
- source wording
- Source null
2 more-specific settings
Study evidence for this setting
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer
E7 TCR T Cells for Human Papillomavirus-Associated Cancers
Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017)
Indication-specific source history
2025-09-09 · gemcitabine intravesical system · approval notification
- release id
- clinical-indications-draft-1
- disease state id
- ds-carcinoma-in-situ
- event id
- notice-23dc13f4d01aeb2e
- event date
- 2025-09-09
- event kind
- approval-notification
- drug or regimen
- gemcitabine intravesical system
- source indication text
- FDA approved gemcitabine intravesical system for adults with Bacillus Calmette-Guérin -unresponsive non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors. Gemcitabine intravesical system is co-packaged with a urinary catheter and stylet used for insertion through the urinary catheter into the bladder.
- match phrase
- carcinoma in situ
- match status
- candidate
- status category
- Source null
- has date discrepancy
- 0
- source collection
- fda-approval-notice
- source key
- fda-a71e076b93797c1c
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
Source relationships and population-mapping limitations
- bindings
- release id
- clinical-indications-draft-1
- disease state id
- ds-carcinoma-in-situ
- binding id
- ncit-C2917
- source collection
- ncit-concept
- source key
- C2917
- source excerpt
- Source null
- match status
- exact
- match note
- Source null
- recorded at
- 2026-09-10T00:00:00Z
- mappings
Download this complete draft source relationship record →
Preserved source evidence · Not medical advice